AngioDynamics, Inc. (ANGO)
| Market Cap | 312.40M |
| Revenue (ttm) | 335.89M |
| Net Income (ttm) | 6.45M |
| Shares Out | 39.85M |
| EPS (ttm) | 0.16 |
| PE Ratio | 49.00 |
| Forward PE | 96.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 321,524 |
| Open | 7.99 |
| Previous Close | 7.99 |
| Day's Range | 7.81 - 7.99 |
| 52-Week Range | 6.01 - 15.96 |
| Beta | 0.65 |
| Analysts | Strong Buy |
| Price Target | 16.33 (+108.29%) |
| Earnings Date | Jan 5, 2024 |
About ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that elim... [Read more]
Financial Performance
In 2023, AngioDynamics's revenue was $338.75 million, an increase of 7.13% compared to the previous year's $316.22 million. Losses were -$52.44 million, 97.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price forecast is $16.33, which is an increase of 108.29% from the latest price.
News
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Completes Enrollment for PRESERVE Clinical Study
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
AngioDynamics to Present at the Needham Virtual Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc.
AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Participate in Three Investor Conferences in March
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc.
AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expa...
AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expa...
AngioDynamics to Present at the Piper Sandler Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expa...
AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism
LATHAM, N.Y.
AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2023 First Quarter Financial Results on October 6, 2022
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Present at the Canaccord Genuity Growth Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
Raymond James Cuts Price Target On AngioDynamics
Raymond James lowered the price target on AngioDynamics Inc (NASDAQ: ANGO) to $27 from $32 based on a 3.0x group multiple applied to the C23 revenue estimate. At 2.2x EV/sales, Raymond James believes ...